Last updated 14 days ago
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
586 patients around the world
Available in Puerto Rico, Brazil, Argentina, United States
Bristol-Myers Squibb
6Research sites
586Patients around the world
This study is for people with
Alzheimer disease
Requirements for the patient
To 85 Years
All Gender
Medical requirements
- Participants must have a confirmed diagnosis of Alzheimer's disease (AD), specifically at the mild (stage 4) or moderate (stage 5) dementia stages, as defined by the National Institute on Aging and Alzheimer's Association (NIA-AA) core clinical criteria. The diagnosis of AD pathology must be confirmed through the 2024 revised NIA-AA Workgroup criteria using a stepwise diagnostic approach.Participants must have an Mini-Mental State Examination (MMSE) score ranging from 12 through 22, inclusive, at the time of screening.Participants must have a designated caregiver who maintains adequate contact (around 10 hours per week or more) and is willing to attend all study visits.The caregiver must also be responsible for reporting on the participant's condition, overseeing medication compliance, and consenting to their involvement in both their own and the participant's study-related activities.Participants on acetyl choline esterase inhibitors (AChEIs) and/or memantine, must have been on a stable dosage for at least 12 weeks prior to screening, and agree to maintain this stable dose for the study duration.
- Participants must not present with any significant or severe medical conditions that could compromise their safety, the ability to comply with or complete the study, or the integrity of the study results. This includes any grade of hepatic impairment.Participants must not have any primary psychiatric diagnoses such as major depression, schizoaffective disorder, or bipolar disorder, and those with severe psychiatric symptoms that could complicate the interpretation of treatment effects, impair cognitive assessment, or impact study completion.Participants must not have a history of schizophrenia or other chronic psychosis, as well as those who have previously been exposed to KarXT or are currently undergoing treatment with disease-modifying anti-amyloid therapies for AD within the past 6 months prior to screening.Participants must not have significant pathological findings on brain magnetic resonance imaging (MRI) at screening that could affect safety or interfere with study procedures.Other protocol-defined Inclusion/Exclusion criteria apply.
Sites
Instituto Médico Damic S.R.L.
Recruiting
CEN Centro Especializado en Neurociencias
Recruiting
Fleni - sede Belgrano
Recruiting
Resolution Psychopharmacology Research Institute
Recruiting
Centro Médico Luquez
Recruiting
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
StudyMINDSET 2
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
Alzheimer disease
Requirements
To 85 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06976203
